Swiss National Bank Lowers Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Swiss National Bank cut its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 3.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 562,000 shares of the company's stock after selling 17,900 shares during the quarter. Swiss National Bank owned 0.31% of Catalent worth $25,251,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Cadian Capital Management LP increased its position in Catalent by 91.0% in the 3rd quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company's stock worth $241,527,000 after purchasing an additional 2,526,750 shares during the last quarter. Barclays PLC raised its position in Catalent by 41.7% during the third quarter. Barclays PLC now owns 4,797,718 shares of the company's stock valued at $218,440,000 after acquiring an additional 1,412,058 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Catalent by 65.9% in the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company's stock valued at $158,601,000 after acquiring an additional 1,384,313 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Catalent by 50.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,536,313 shares of the company's stock worth $69,948,000 after acquiring an additional 516,464 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Catalent by 29.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,875,829 shares of the company's stock valued at $85,406,000 after purchasing an additional 428,260 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CTLT. UBS Group reiterated a "neutral" rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, February 20th. Barclays boosted their target price on shares of Catalent from $45.00 to $47.00 and gave the stock an "equal weight" rating in a research report on Thursday, January 25th. StockNews.com initiated coverage on Catalent in a research report on Sunday. They issued a "sell" rating on the stock. Finally, Stephens restated an "equal weight" rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, April 4th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $52.46.

Catalent Stock Performance

Catalent stock traded down $0.25 on Thursday, hitting $55.95. The company's stock had a trading volume of 1,931,857 shares, compared to its average volume of 2,454,729. Catalent, Inc. has a one year low of $31.45 and a one year high of $60.20. The firm has a market cap of $10.13 billion, a P/E ratio of -8.23, a price-to-earnings-growth ratio of 6.09 and a beta of 1.18. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. The company has a fifty day moving average price of $56.34 and a 200-day moving average price of $49.36.

Catalent (NYSE:CTLT - Get Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.21 by ($0.36). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.11 billion. On average, equities analysts anticipate that Catalent, Inc. will post 0.28 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.